OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics
- Details
- Category: Bayer
OncoTrack, an international consortium of over 60 scientists, managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics, has launched one of Europe's largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer.
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
FDA accepts new drug application for investigational compound Dapagliflozin
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
- Details
- Category: Genzyme
Genzyme Corporation (NASDAQ: GENZ) announced that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share.
Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints
Bayer extends support to fight Chagas disease
- Details
- Category: Bayer
Bayer HealthCare today signed an extension of its agreement with the World Health Organization (WHO) to fight Chagas disease, a deadly and neglected tropical disease (NTD). The five-year extension will come into effect in April 2012, when the previous agreement signed in 2007 had been set to expire.
Breakaway From Cancer(R) Launches Newly-Enhanced Website
- Details
- Category: Amgen
As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning cancer prevention, education, patient care, advocacy, and financial support.
More Pharma News ...
- Breaking the Taboo Associated with Hemorrhoidal Disease
- Nycomed well positioned in emerging markets
- Roche Annual General Meeting: dividend raised by 10%
- Nycomed's novel COPD therapy roflumilast receives FDA approval
- Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
- Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab)
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy